Pharming Total Assets from 2010 to 2026
| PHARM Stock | EUR 1.44 0.04 2.86% |
Total Assets | First Reported 2009-12-31 | Previous Quarter 446.3 M | Current Value 473.8 M | Quarterly Volatility 162.7 M |
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.3 M, Interest Expense of 6.6 M or Selling And Marketing Expenses of 7.8 M, as well as many indicators such as Price To Sales Ratio of 2.43, Dividend Yield of 0.0 or PTB Ratio of 3.82. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
Pharming | Total Assets |
Analyzing Pharming Group's Total Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Assets has evolved provides context for assessing Pharming Group's current valuation and future prospects.
Latest Pharming Group's Total Assets Growth Pattern
Below is the plot of the Total Assets of Pharming Group NV over the last few years. Total assets refers to the total amount of Pharming Group assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Pharming Group NV books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Pharming Group's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 386.88 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Pharming Total Assets Regression Statistics
| Arithmetic Mean | 239,431,161 | |
| Geometric Mean | 157,224,589 | |
| Coefficient Of Variation | 72.67 | |
| Mean Deviation | 154,506,284 | |
| Median | 245,446,122 | |
| Standard Deviation | 173,983,231 | |
| Sample Variance | 30270.2T | |
| Range | 444.9M | |
| R-Value | 0.96 | |
| Mean Square Error | 2668T | |
| R-Squared | 0.92 | |
| Slope | 32,999,665 | |
| Total Sum of Squares | 484322.6T |
Pharming Total Assets History
About Pharming Group Financial Statements
Pharming Group stakeholders use historical fundamental indicators, such as Pharming Group's Total Assets, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pharming Group's assets and liabilities are reflected in the revenues and expenses on Pharming Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pharming Group NV. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Assets | 444.9 M | 467.2 M | |
| Intangibles To Total Assets | 0.18 | 0.21 |
Thematic Opportunities
Explore Investment Opportunities
Check out the analysis of Pharming Group Correlation against competitors. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.